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Phenotypic screening identified an arylsulfonamide compound with activity against 19 
Trypanosoma cruzi, the causative agent of Chagas’ disease. Comprehensive mode of action 20 
studies revealed that this compound primarily targets the T. cruzi proteasome, binding at the 21 
interface between β4 and β5 subunits that catalyse chymotrypsin-like activity. A mutation in the 22 
β5 subunit of the proteasome was associated with resistance to compound 1, while 23 
overexpression of this mutated subunit also reduced susceptibility to compound 1. Further 24 
genetically engineered and in vitro selected clones resistant to proteasome inhibitors known to 25 
bind at the β4/β5 interface were cross-resistant to compound 1. Ubiquitinylated proteins were 26 
additionally found to accumulate in compound 1-treated epimastigotes. Finally, thermal 27 
proteome profiling identified malic enzyme as a secondary target of compound 1, although malic 28 
enzyme inhibition was not found to drive potency. These studies identify a novel 29 
pharmacophore capable of inhibiting the T. cruzi proteasome that may be exploitable for anti-30 




The protozoan parasite Trypanosoma cruzi is the etiological agent of Chagas’ disease, also 33 
known as American trypanosomiasis. This zoonotic disease is endemic in Latin American 34 
countries where an estimated 6–7 million individuals across 21 countries are infected. Due to 35 
migration from endemic countries, Chagas’ disease is now a worldwide problem, with hundreds 36 
of thousands of infected individuals now residing in the United States and Europe. The acute 37 
stage of Chagas’ disease has very mild and non-specific symptoms that occur 4–8 weeks post-38 
infection. As a result, very few infections are diagnosed at this stage. However, in ~30% of 39 
individuals, infection manifests as a symptomatic chronic condition, although this can take many 40 
years to emerge (1). Most commonly, chronic disease is associated with cardiac dysfunction, 41 
and to a lesser extent, digestive tract pathologies. These sequelae result in the death of 42 
~12,500 people each year (2). 43 
To date, benznidazole (2-nitroimidazole) and nifurtimox (5-nitrofuran) are the only 44 
approved drugs available for the treatment of Chagas’ disease. Prolonged treatment with these 45 
nitroimidazoles during the acute stage cures up to 70% of individuals; however, their efficacy 46 
decreases significantly in the chronic stage (3). Both therapies are associated with severe toxic 47 
side effects that can lead to the interruption or discontinuation of treatment in as many as 30% 48 
of cases (4, 5). It is clear that new, safe, effective, oral drugs that are suitable for short-course 49 
regimens are urgently required.  50 
No new drugs have been developed for Chagas’ disease for over 30 years.  Recent 51 
clinical trials with posaconazole and the ravuconazole prodrug E1224, were disappointing with 52 
relapse in between 70-90% of patients (6, 7), compared with to 6-30% failure for the 53 
benznidazole-treated arm of the study. The failure of both azoles, known to act via inhibition of 54 
lanosterol C14α-demethylase (CYP51), has led to a “root and branch” overhaul of the screening 55 
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cascade and drug discovery approach for Chagas (8, 9). The principal goal of this process will 56 
be to vastly improve translation from in vitro and in vivo models for Chagas’ disease to the clinic. 57 
Successful treatment of Chagas’ disease is now believed to require removal of every 58 
viable parasite within the infected patient. To complicate matters further, transiently dormant or 59 
persister forms of T. cruzi that are refractory to drugs acting via certain mechanisms of action 60 
(MoA) have recently been identified (10, 11). An additional barrier to the development of new 61 
drugs is the relative lack of robustly validated targets in T. cruzi. This has limited target-focused 62 
screening programs and led to a reliance upon phenotypic screening to identify start points for 63 
drug discovery. Phenotypic approaches have proven effective, however, a lack of information 64 
regarding the MoA or specific molecular target(s) of active compounds can hinder their 65 
downstream optimization in order to overcome pharmacokinetic and/or toxicity issues and to 66 
derive selectivity compared to human homologues. Furthermore, a comprehensive 67 
understanding of MoA can facilitate the deprioritization of compounds with unattractive or failed 68 
targets, such as CYP51, or those unable to clear all parasites and/or kill persister forms, as well 69 
as allowing the triaging of compounds targeting the same, promising targets.  70 
Here, we use a range of genetic and chemical proteomic approaches to determine the 71 
MoA of an arylsulfonamide compound demonstrating promising in vitro activity against T. cruzi. 72 
Our comprehensive studies reveal that this compound principally targets the T. cruzi 73 
proteasome, binding at the interface between the β4 and β5 subunits that catalyse 74 
chymotrypsin-like peptidase activity. Using thermal proteome profiling, we also confirm that this 75 
compound interacts with a secondary target, malic enzyme, albeit this interaction does not 76 
appear to drive potency. The implications of developing compounds with this MoA as anti-77 





Compound 1 was kindly provided by GlaxoSmithKline. The malic enzyme inhibitor ATR-073 was 81 
purchased from MolPort. DDD01012248 (12) and GNF6702 (13) were kindly provided by the 82 
Drug Discovery Unit, University of Dundee. Bortezomib was purchased from Sigma-Aldrich. The 83 
structures of all compounds used in this study are shown in Figure 1. 84 
 85 
Cell lines and culture conditions 86 
The clonal Leishmania donovani cell line LdBOB (derived from MHOM/SD/62/1S-CL2D) was 87 
grown as either promastigotes or axenic amastigotes in media-specific for each developmental 88 
stage, as previously described (14). T. cruzi epimastigotes from the Silvio strain 89 
(MHOM/BR/78/Silvio; clone X10/7A, (15)) were grown at 28°C in RTH/FBS [RPMI 1640 medium 90 
supplemented with trypticase, haemin, Hepes and 10% heat-inactivated FBS (Fisher Scientific) 91 
(16). Bloodstream form T. brucei  “single marker” S427 (T7RPOL TETR NEO) were cultured in 92 
the presence of G418 (15 μg mL–1) at 37 °C in HMI9-T media in the presence of 5% CO2. Hep 93 
G2 cells (ECACC 85011430) were obtained from European Collection of Authenticated Cell 94 
Culture (ECACC). Cells were maintained in full growth medium (MEM with Glutamax 95 
(ThermoFisher), supplemented with 1% MEM non-essential amino acids (Sigma) and 10% heat-96 
inactivated FBS and cultured at 37°C in the presence of 5% CO2.  Cells were passaged twice 97 
weekly by detaching adherent cells with 0.05% trypsin/EDTA (Sigma) and diluted into fresh 98 
media. Cells were never grown beyond 80% confluency. Vero cells (African green monkey 99 
kidney cells, ECCAC 84113001) were maintained at 37°C, 5% CO2 in Dulbecco's modified 100 
Eagles's medium (DMEM, Lonza) supplemented with 10% FCS and sub-cultured every 2 days. 101 




-1) cultures after ~7 -10 days at 28°C in RTH/FBS. Trypomastigote-rich cultures were 103 
incubated with Vero cells overnight at 37°C 5% CO2 in DMEM/10% FCS. The following day, 104 
extracellular parasites were removed by washing the Vero cell monolayer three times. Infected 105 
monolayers were maintained at 37°C 5% CO2 and DMEM/10% FCS replaced every 48 h until 106 
trypomastigotes re-emerged from Vero cells (9).  107 
 108 
Drug sensitivity assays  109 
To examine the effects of test compounds on the growth of T. cruzi epimastigotes, mid-log 110 
parasites were seeded into 96 well plates at a cell density of 5 × 105 cells·mL−1. Cells were 111 
exposed to test compounds over a range of concentrations (two-fold serial dilutions). Cells were 112 
incubated for 4 days, after which 20 μL 2.5 mM resazurin was added to each well, before 113 
measuring fluorescence (excitation of 528 nm and emission of 590 nm), after a further 24 h 114 
incubation. Data were processed using GRAFIT (Erithacus software) and fitted to a 2-parameter 115 
equation, where the data are corrected for background fluorescence, to obtain the effective 116 




















In this equation, [I] represents inhibitor concentration and m is the slope factor. Experiments 119 
were repeated at least two times, and the data is presented as the mean plus standard 120 
deviation. 121 
L. donovani promastigote (17), axenic amastigote (18) and T. brucei bloodstream form 122 
(19) drug sensitivity assays were carried out as previously described. HepG2 monolayers were 123 
washed twice in PBS, then detached with 0.05% trypsin/EDTA, and diluted with fully 124 
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supplemented MEM growth medium.  Cells were pelleted at 80 ×g for 5 min and resuspended in 125 
fully-supplemented growth medium.  Cells were seeded into 96-well plates (5 × 104/well) and 126 
allowed to adhere prior to exposure to test compounds. Plates were incubated at 37°C in the 127 
presence of 5% CO2 for 72 h. Following incubation, resazurin (20 µL of a 2.5 mg/mL
-1 stock 128 
solution) was added to each well, incubated for a further two hours prior to fluorescence being 129 
read as described. 130 
Drug sensitivity assays against T. cruzi-infected Vero cells were carried out as 131 
previously described (20),  however in this instance assays were carried out in 96-well plates. 132 
Data were processed using GRAFIT (Erithacus software) and fitted to a 2-parameter equation, 133 
as described above. 134 
 135 
Cosmid library screening 136 
The construction of our cosmid-based genome-wide overexpression library in L. donovani and 137 
strategy used to screen the library have been described in detail previously (18). For compound 138 
2 (Figure 1), the library was selected for 2 days at 8 nM, 2 days at 16 nM and a further 12 days 139 
at 30 nM prior to harvesting and analysis. For compound 1 (Figure 1), the library was selected 140 
for 7 days at 300 nM and for a further 14 days at 600 nM. The associated data sets have been 141 
deposited with the European Nucleotide Archive under the following accession number: 142 
PRJEB39157. 143 
 144 
Resistance generation 145 
Compound-resistant cell lines were generated by subculturing a clone of wild-type T. cruzi 146 
epimastigotes in the continuous presence of compound 1. Starting at sublethal concentrations, 147 
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drug concentrations in 5 independent cultures were increased in a stepwise manner. When 148 
parasites were able to survive and grow in concentrations of compound 1 equivalent to >20x the 149 
established EC50 value, the resulting cell lines were cloned by limiting dilution in the presence of 150 
compound. Five clones (RES 1-5) were selected for further biological study.  151 
 152 
Whole genome sequencing analysis 153 
Genomic DNA was isolated from WT and resistant clones using a standard alkaline lysis 154 
protocol. DNA was sequencing on an Illumina 4000 machine by the Beijing Genomics Institute 155 
(BGI). Sequences reads were aligned to the T. cruzi Sylvio x10 (v39) or T. cruzi Dm28c 2018 156 
genome sequence (v46; tritrypdb.org) alongside the maxi-circle sequence (FJ203996.1, NCBI). 157 
Reads were aligned using Bowtie2 using the settings “--very-sensitive” and Samtools software. 158 
Single nucleotide polymorphisms (SNPs) and indels were called using Samtools (mpileup) and 159 
BCFtools (21) where overall quality score (QUAL) was >100 when compared with the wild type 160 
starter clone. Chromosome and gene copy number variation (CNV) analysis, as well as 161 
visualisations, was performed using Artemis. Median read counts of the wild type and resistant 162 
clones were used to normalise copy number. The associated data sets have been deposited 163 
with the European Nucleotide Archive under the following accession number: PRJEB39157.  164 
 165 
Lysate production for thermal proteome profiling (TPP) 166 
T. cruzi (X10/7 strain) mid-log epimastigotes (~1×1010) were harvested by centrifugation (1912 167 
×g, 15 min, 4ºC), washed with ice-cold PBS (1912 ×g, 5 min, 4 ºC),  and finally the cell pellet 168 
was resuspended in 8 mL ice-cold lysis buffer (1 mM EDTA, 1 mM DTT, 100 µM TLCK and 1× 169 
Roche EDTA-free COmplete protease inhibitor cocktail in 50 mM potassium phosphate buffer, 170 
pH7.4). The cell suspension was submitted to 3 freeze-thaw cycles in a dry ice/ethanol bath to 171 
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biologically inactivate the parasites and then submitted to cell disruption (Constant Systems, 172 
UK) at 30 kpsi. The resulting lysate was centrifuged (100,000 ×g, 20 min, 4ºC), supernatant was 173 
collected, and the protein concentration was determined using the Bio-Rad Protein Assay. 174 
 175 
TPP assays 176 
The lysate concentration was adjusted to 2.5 mg mL-1 with lysis buffer and then 2 × 2 mL 177 
aliquots were incubated at room temperature for 30 min in the presence of test compound at 20 178 
µM (equivalent to 10×EC50) or vehicle (0.1% DMSO). Each 2-mL aliquot (drug and vehicle 179 
treated) was divided into 10 × 100 µL aliquots in 0.5-mL thin–walled PCR tubes and incubated 180 
at a designated temperature (33, 37, 41, 45, 49, 53, 57, 61, 65 or 69ºC) for 3 min followed by 181 
incubation at RT for 3 min before each sample was placed on ice. Each aliquot was centrifuged 182 
(100,000 ×g, 20 min, 4 ºC), supernatants were harvested, and the protein concentration was 183 
assessed.  184 
 185 
TPP sample processing, analyses and data processing 186 
All aspects of sample processing, peptide and protein identification and quantitation; and target 187 
identification were carried out as previously described (22). However, in this instance, proteins 188 
were identified by searching the MS and MS/MS data for the peptides against T. cruzi proteome 189 
Dm28c 2018 version 50 (https://tritrypdb.org/tritrypdb). 190 
 191 
Generation of overexpression constructs 192 
Malic enzyme (TcME, C4B63_28g106) β5 (Tcβ5WT, C4B63_48g131) and β5D225N (Tcβ5D225N) 193 
overexpression constructs were assembled by inserting synthetic versions of each gene 194 
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(GeneArt, Invitrogen) into the pTREX vector via EcoRI and XhoI sites (23). The L. donovani 195 
malic enzyme (LdBPK_240780.1) overexpression construct was assembled by inserting a 196 
synthetic version of the gene (GeneArt) into the pIR1SAT vector via BglII sites. All 197 
overexpression constructs were sequenced in-house to confirm their accuracy. T. cruzi 198 
overexpression constructs were linearised with NheI prior to transfection.  199 
 200 
Generation of CRISPR-cas9 edited T. cruzi cell line 201 
T. cruzi proteasome β4 subunit base editing was achieved by mixing a Cas9 expression plasmid 202 
(10 µg), a specific sgRNA template, a repair template (40 µg) and T7 RNA polymerase; then 203 
transfecting the mixture into T. cruzi epimastigotes. Briefly, pRPaT7Cas9 was assembled by 204 
replacing the rDNA promoter in pRPaCas9 (24) with a T7 promoter. pRPaCas9 was digested with 205 
NheI and HindIII to remove the rDNA promoter and replaced by the following sequence 206 
containing the T7 promoter: 207 
GCTAGCTAATACGACTCACTATAGGGCCCTGCACGCGCCTTCGAGTTTTTTTTCCTTTTCC208 
CCATTTTTTTCAACTTGAAGACTTCAATTACACCAAAAAGTAAAATTCACAAGCTT. 209 
Restriction sites are underlined, and T7 promoter sequence is bold. The remaining sequence 210 
corresponds to an untranslated region upstream of the procyclin gene that was removed with 211 
the rDNA promoter and needs to be reinstated for the correct processing of Cas9 mRNA. The 212 
sgRNA template was generated by annealing and end-filling the FTcProtB4g and R-uni-scaf 213 
oligonucleotides: FTcProtB4g 214 
(TAATACGACTCACTATAGGGCATCAAGATCATGGACACGGGTTTTAGAGCTAGAAATAGC215 
AAG), the T7 promoter is underlined, the specific gRNA target sequence is bold and the partial 216 




TCTAGCTCTAAAAC), the full sgRNA scaffold sequence. These oligonucleotides (both at 2 M) 219 
were annealed at 50°C and end-filled at 72°C for 15 sec (5 cycles) in the presence of HiFi 220 
polymerase (Roche). The repair template was FTcProtB4g: 221 
(TAGCAGCAGCAGGGCTGAATGCCTTATACTATATTAAAATGATGGATACAGAAGATAAGGT222 
CACGCAGTTGGATTCCC); non-synonymous edits are bold and synonymous changes are 223 
underlined, one of which disrupts the Cas9 protospacer-adjacent motif to prevent further DNA 224 
breaks. The three DNA components were combined, ethanol precipitated, resuspended in 10 µL 225 
of dH2O and, following addition of 5 µL of T7 RNA polymerase, electroporated into T. cruzi 226 
epimastigotes, as described below. Cells were allowed to recover for 24 h, then selected with 227 
GNF6702 at 1.5 µM. Resistant cells were subcloned, DNA was extracted from independent 228 
subclones, and a specific portion of the T. cruzi proteasome β4 gene (TCSYLVIO_007432) 229 
encompassing the edited region, was amplified using the following PCR primers: FB4-PCR 230 
(atgtcggagacaaccattgcttttc) and RB3-PCR (ccatgtagtacaagtgtggtcc). The PCR products were 231 
Sanger sequenced in-house. 232 
 233 
Transfection of L. donovani and T. cruzi transgenic cell lines 234 
Mid-log-epimastigotes (2 × 107 cells in total) were transfected with 5 – 10 µg of overexpression 235 
constructs using the Human T-Cell Nucleofector kit and Amaxa Nucleofector electroporator 236 
(program U-033). Following transfection, cells were allowed to recover for 16-24 h, before the 237 
appropriated drug selection (200 μg mL−1 G418). L. donovani transgenic cell lines were 238 
generated as previously described (25) and selected with nourseothricin (100 µg mL-1). In all 239 
cases, cloned cell lines were generated by limiting dilution, maintained in selective medium and 240 




RT-qPCR  243 
RNA was harvested from mid-log epimastigotes (1 × 108 cells total) using the RNeasy Mini Kit 244 
(Qiagen), as per the manufacturer’s instructions. The remaining DNA was degraded from 245 
samples using the RNase-Free DNase Set (Qiagen). Quantitative RT-PCR was performed with 246 
100 ng of total RNA using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs) 247 
with the following reaction conditions: 10 min at 55°C for the reverse transcription step, followed 248 
by a denaturation step of 1 min at 95°C and then by 40 cycles of 10 s at 95°C; finally extension 249 
for 30 s at 60°C. Relative quantification was established using the reference gene 250 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers (listed below), were designed 251 
using the Primer3Plus website. The levels of each transcript in the overexpression cell lines 252 
were normalised to wild-type using the ΔΔCt method. Two independently transfected clones for 253 
each construct were used, and statistical significance was measured using a student’s unpaired 254 
t test. 255 
 256 
Label-free quantification 257 
Relative protein abundance in WT versus overexpressing cell lines was established as 258 
previously described (18). In this instance proteins were identified by searching protein 259 
sequence database containing L. donovani BPK282A1 or T. cruzi Dm28c annotated proteins 260 
(downloaded from TriTrypDB 46, http://www.tritrypdb.org). 261 
 262 
Proteasome assays 263 
Proteasome assay – luminescence 264 
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The effect of inhibitors on the chymotrypsin-like activity of the T. cruzi proteasome was 265 
assessed via a luminescence-based assay, as previously described (26). 266 
 267 
Proteasome assay - treatment with proteasome inhibitors and lysate preparation 268 
T. cruzi epimastigotes in the logarithmic growth phase (3 × 106 cells mL-1) were incubated for 269 
12h with bortezomib (1.8 µM), GNF6702 (2.9 µM) (Figure 1) or compound 1 (24 µM), equivalent 270 
to 8× the EC50 values of each compound. Controls were incubated in the presence of diluent 271 
(DMSO). Cells were harvested by centrifugation (1912 ×g, 15 min, 4 °C) and washed with ice-272 
cold PBS (1912 ×g, 5 min, 4 °C), and finally, the cell pellets were resuspended in 1.5 mL of ice-273 
cold lysis buffer (1 mM EDTA, 1 mM DTT, 100 μM TLCK, and 1× Roche EDTA-free cOmplete 274 
protease inhibitor cocktail in 50 mM potassium phosphate buffer, pH 7.4). Cell suspensions 275 
were submitted to 3 freeze–thaw cycles in a dry ice/ethanol bath to biologically inactivate the 276 
parasites and then lysed using the One ShotTM Cell disruptor (Constant Systems, UK) at 30 277 
kpsi.  278 
 279 
Proteasome assay - sample processing and enrichment 280 
Cell lysates were centrifuged (100,000 ×g, 20 min, 4°C), supernatants were collected, and the 281 
protein concentrations were determined using a standard Bio-Rad protein assay. Aliquots (1.1 282 
mg) were reduced by incubating with 25 mM Tris(2-carboxyethyl)phosphine hydrochloride 283 
(TCEP) for 10 min at 37 °C and alkylated by incubating with 25 mM iodoacetamide (IAA) for 1 h 284 
at RT in the dark. Samples were then precipitated by incubating with 10% (v/v) trichloroacetic 285 
acid (TCA) for 3 h at -20 ºC then washed ×3 with ice-cold acetone. Protein pellets were 286 
resuspended in 100 mM triethylammonium bicarbonate (TEAB) and digested with 40 µg Lys-C 287 
for 6 h followed by 40 µg trypsin overnight (25:1 protein:enzyme ratio). Protein digests were 288 
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dried via evaporation, and the digestion efficiency was checked by mass spectrometry. Small 289 
aliquots of each sample (9% of the total sample) were kept for total proteome analysis, with the 290 
remainder submitted to enrichment. Ubiquitinated proteins were enriched using the PTMScan 291 
HS Ubiquitin/SUMO Remnant Motif (K-ε- GG) Kit (Cell Signalling Technologies) following the 292 
manufacturer’s recommendations. This kit contains antibodies conjugated to magnetic beads 293 
that specifically recognise the remnant of ubiquitinated lysines following digestion with trypsin 294 
and/or LysC. This remnant consists of a Gly-Gly (diGly) motif bound to the ε-amine of lysine 295 
through an isopeptide bond. Lysine ubiquitination results in a mis-cleavage, as tryptic enzymes 296 
are not able cut after ubiquitinated lysines. Briefly, dried digests were resuspended in HS IAP 297 
Bind Buffer and incubated with magnetic beads conjugated to antibodies recognising the anti-K-298 
ε- GG motif for 2h at 2°C. Then, the beads were washed with HS IAP Wash buffer and water to 299 
remove unbound peptides. Bound peptides were eluted by incubating in agitation with IAP 300 
elution buffer (0.15 % trifluoroacetic acid, TFA) for 10 min. Eluates were then dried under 301 
vacuum and labelled with TMTs using the TMT 10plex isobaric tagging kit (Thermo Scientific) as 302 
follows: 126, 127N, 127C and 128N, were used to label control, GNF6702, bortezomib and 303 
compound 1 samples, respectively, in parallel with their respective (total) proteome samples. 304 
After 1h, the reaction was quenched by the addition of 5% hydroxylamine for 15 min, and then 305 
the four samples were pooled and vacuum-dried. The two pooled samples (total proteome and 306 
enriched fraction) were desalted using the Pierce™ Peptide Desalting Spin Columns (Thermo) 307 
and the eluates vacuum-dried. 308 
 309 
Proteasome assay - LC-MS/MS 310 
Analysis of peptides was performed on a Q-Exactive-HF (Thermo Scientific) mass spectrometer 311 
coupled to a Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers used were as follows: 312 
Buffer A (0.1% formic acid in Milli-Q water (v/v)) and Buffer B (80% acetonitrile and 0.08% 313 
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formic acid in Milli-Q water (v/v)). Aliquots of each sample (1 μL) were loaded at 5 µL/min onto a 314 
trap column (100 μm x 2 cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) 315 
equilibrated in 5% Buffer B. The trap column was washed for 5 min at the same flow rate and 316 
then switched in-line with a Thermo Scientific, resolving C18 column (75 μm x 50 cm, PepMap 317 
RSLC C18 column, 2 µm, 100 Å). Peptides were eluted from the column at a constant flow rate 318 
of 300 nL/min-1 with a linear gradient from 5% Buffer B (for fractions 1-10, 7% for fractions 11-319 
20) to 35% Buffer B in 130 min, and then to 98% Buffer B at 132 min. The column was then 320 
washed with 98% Buffer B for 20 min and re-equilibrated in 5% buffer B for 17 min. Q-Exactive 321 
HF was used in data-dependent mode. A scan cycle comprised MS1 scan [m/z range from 335-322 
1800, with a maximum ion injection time of 50 ms, a resolution of 120,000 and automatic gain 323 
control (AGC) value of 3 × 106] followed by 15 sequential dependant MS2 scans (with an 324 
isolation window set to 0.7 Da, resolution at 60,000, maximum ion injection time at 200 ms and 325 
AGC 1 × 105). To ensure mass accuracy, the mass spectrometer was calibrated on the first day 326 
that the runs are performed. 327 
 328 
Protein search and data analysis 329 
MS data were analysed using the software MaxQuant (http:// https://maxquant.net/maxquant/, 330 
version 2.0.1.0). For the enriched fractions, Reporter ion MS2 mode  was selected using N-331 
terminus TMT10plex and Carbamidomethyl (C) as fixed modifications while oxidation (M), acetyl 332 
(Protein N-term), Lysine TMT10plex, DiGly and a set of DiGly-Lysine TMT10plex modifications 333 
were set as a variable modifications. Proteins were identified by searching the MS and MS/MS 334 
data for the peptides against Trypanosoma cruzi Dm28c proteome (TriTrypDB version 50, 335 
tritrypdb.org). Trypsin/P and LysC/P were selected as the digestive enzymes. For the total 336 
proteome samples, Reporter ion MS2 mode was selected using the TMT-10plex labels on N-337 
terminus and lysine;  Carbamidomethyl (C) was set as fixed modification while oxidation (M), 338 
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acetyl (Protein N-term) were set as variable modifications. Protein abundance was calculated 339 
according to the normalized reporter ion intensities, which for the enriched fractions were 340 
calculated using only DiGly-modified peptides. The FDR threshold for peptides and proteins was 341 
0.01. Two missed tryptic cleavages were allowed in the global proteome samples while three in 342 
the enriched fractions, FTMS MS/MS mass tolerance was set to 10 ppm and ITMS MS/MS 343 
mass tolerance was 0.06 Da. The mass spectrometry proteomics data have been deposited to 344 
the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier 345 
PXD027524. Data were analysed using the Perseus software (https://maxquant.net/perseus/, 346 
version 1.6.15.0) and RStudio (version 1.2.5033). 347 
 348 
Malic enzyme assays 349 
Logarithmic T. cruzi epimastigotes were harvested (1,690 ×g, 10 min, 4°C), washed once in ice 350 
cold PBS and resuspended at 2 × 109 cells mL-1 in lysis buffer (10 mM phosphate buffer, pH 7.2, 351 
10 mM EDTA, 5 mM benzamidine, 5 mM phenanthroline, 0.1 mM PMSF) containing 1 mg mL-1 352 
digitonin and incubated at 28 °C for 10 min. The resulting lysate was then centrifuged (13,000 353 
×g, 10 min, 4°C) supernatant harvested and stored on ice. The protein concentration of this 354 
clarified lysate was determined via a standard Bio-Rad protein assay. 355 
The activity of malic enzyme was assayed as previously described (27), with minor 356 
modifications. T. cruzi clarified lysate (30 µL) was added to a reaction mixture (500 µL final 357 
volume) containing 50 mM Tris-HCl buffer pH 7.6, 1 mM MnCl2 and 0.12 mM NADP
+. Reactions 358 
were initiated by the addition of 5 mM L-malate. The reduction of NADP+ was monitored at 340 359 
nm using a UV-2401 spectrophotometer (Shimadzu). To monitor the effect of test compounds 360 
on the activity of malic enzyme, compounds (1 and 20 µM) were pre-incubated for 10 min with 361 
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the lysate in the reaction mixture. DMSO (0.2%) was used as control. All enzymatic activities 362 
were calculated as Δabs min-1 mg-1 protein. 363 
 364 
Homology model 365 
A model of the subunits 4 and 5 of the T. cruzi proteasome was generated using Modeller 366 
[version 9.24, https://www.salilab.org/modeller/, (28)] based on K and L chains of the L. 367 
tarentolae proteasome co-crystallized with compound GSK3494245 (PDB: 6QM7). T. cruzi  4 368 
(C4B63_13g138) and 5 (C4B63_48g131) sequences were aligned to the L. tarentolae 369 
template using the alignment 2D function in Modeller (Figure S2). A set of 5 models were 370 
generated with the GSK3494245 compound in the binding site, and the best ranked, based on 371 
Modeller scores, was chosen for docking calculations. 372 
 373 
Docking  374 
Ionization states and tautomers for compound 1 were assigned using LigPrep (Schrödinger) at 375 
the default pH range (7  2).  Pyrazole tautomerism indicated two equally populated tautomers 376 
and both were used for subsequent docking calculations. The T. cruzi model was refined and 377 
optimized using Protein preparation wizardi: hydrogen bond networks were optimized for 378 
hydroxyls, thiols and sidechain amide groups of the protein residues (Ser, Tyr, Cys, Asn and 379 
Gln, respectively). Tautomers were evaluated for imidazole rings (His) and optimised. 380 
Protonation states of charged residues (His, Asp, Glu, Arg and Lys) were evaluated. 381 
Optimisation was carried out using OPLS3e forcefield and VSGB implicit solvation model. A grid 382 




Molecular electrostatic potential 385 
Electrostatic potential (ESP) maps were generated on the ligand binding pose using DFT 386 
method in Jaguar at B3LYP-D3/6-31+G(d,p) level of theory. ESP surfaces were represented 387 
using 0.001 isovalue, and surfaces were mapped on the electrostatic potential using rainbow 388 
colour scale. Protein ESP was generated using the Electrostatic potential surface panel in 389 
Maestro by solving the Poisson-Boltzmann equations using the atomic partial charges of the 390 
protein residues (Schrödinger). The docking protocol XP was used using default settings which 391 
include a post docking minimisation step.  392 
  393 
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Results  394 
An arylsulfonamide compound demonstrating promising activity against T. cruzi. 395 
High-throughput screening of GSK’s 1.8M compound library against L. donovani, T. cruzi and T. 396 
brucei resulted in the identification of a significant number of compounds active against these 397 
parasites (29). Among these hits, TCMDC-143194 was found to be moderately active against all 398 
three kinetoplastids (compound 1, Figure 1), with EC50 values ranging between 0.1 and 8 µM 399 
against the mammalian stages of these parasites (Table 1). Bearing in mind the paucity of well-400 
validated molecular targets for Chagas drug discovery and the fact that compound 1 does not 401 
act through inhibition of CYP51 [CYP51 pIC50 – 4.4, (29)], we proceeded with target 402 
identification studies predominantly in T. cruzi. 403 
 404 
Resistance generation followed by whole genome sequencing (WGS) 405 
Our first step towards determining the MoA of compound 1 was to select T. cruzi epimastigote 406 
cell lines resistant to this arylsulfonamide. Starting at 3 µM (~1 × EC50), five independent clonal 407 
lines of compound-susceptible parasites were exposed to stepwise increasing levels of 408 
compound 1 for 40-60 days, until they were routinely growing at concentrations equivalent to 409 
10-20× the established EC50 value (Figure 2A). The five independently generated resistant cell 410 
lines were cloned by limiting dilution, and clones were assessed for susceptibility to compound 411 
1. The resulting clones were between 9 -21-fold less sensitive to compound 1 than the wild-type 412 
parental clone (Figure 2B and Table 2). In each case, the resistance demonstrated by each 413 
clone was stable over 20 passages in culture in the absence of compound. 414 
Genomic DNA recovered from the five resistant clones was analysed by WGS. 415 
Sequence reads were aligned to both T. cruzi Dm28c or Sylvio X10 reference genomes and 416 
compared to the wild-type parental clone (data summarised in Tables S2 and S3). Analysis of 417 
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single nucleotide polymorphisms (SNPs) of resistant lines RES 1-3 identified a homozygous 418 
mutation (D225N) in the β5 subunit of the proteasome (C4B63_48g131). In addition, pre-419 
existing heterozygosity at position 54 (I/T) within β5 in the parental cell line became 420 
homozygous for Thr in all resistant lines. In line RES 5, a homozygous SNP (I27T) was also 421 
identified on the β4 subunit of the proteasome. Of the 5 compound 1-resistant clones, only RES 422 
4, the least resistant of the 5 lines (9-fold), bore no mutations in any subunits of the proteasome. 423 
Instead, RES 4 maintains a homozygous SNP (V253L) in an ABCG-like transporter 424 
(C4B63_63g86), a homologue of a Leishmania transporter with an established link to drug 425 
resistance (30, 31), as well as a heterozygous SNP (H605Q) on mitochondrial DNA polymerase 426 
I protein D. Relatively few copy number variations (CNV) were observed in resistant clones in 427 
comparison to the parental. Extra copies of the proteasome regulatory ATPase subunit 5 428 
(C4B63_76g37) and subunit 1 (C4B63_76g43) were identified in RES 2, 3 and 4, with both 429 
genes encoded on the same contig.  430 
 431 
Screening of compound 1 against a genome-wide overexpression library 432 
As a parallel approach to identify the molecular target, compound 1 was screened against our 433 
genome-wide overexpression library in the closely related kinetoplastid parasite Leishmania 434 
donovani (22). The principle under-pinning this gain-of-function screen is that elevated levels of 435 
a drug target can result in resistance to the corresponding drug by increasing the pool of 436 
functional protein or by reducing free drug through binding. L. donovani promastigotes were 437 
transfected with a pooled population of cosmids containing genomic DNA fragments of between 438 
35 and 45 kb. The final transfected library provides a >15-fold genome coverage with 99% of 439 
Leishmania genes represented. The library was selected with 300 nM compound 1 (equivalent 440 
to the EC99 in promastigotes) for 7 days and for a further 14 days at 600 nM. Following 441 
compound selection, cosmids maintained by the “resistant” parasite population were harvested 442 
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and analysed by next-generation sequencing. Mapping of overexpressed inserts to the L. 443 
donovani LV9 and BPK281 assembled genomes revealed that 80% of all mapped reads aligned 444 
to a single region on chromosome 35 (Figures 2C, Tables S4 and S5). This 63.3 kb region 445 
encodes 14 designated open reading frames (ORFs) in total. However, only two genes were 446 
flanked by all opposing barcodes: a CBS domain-containing protein (LdBPK.35.2.000780), also 447 
annotated as the γ subunit of an AMP-activated protein kinase, and the proteasome-activating 448 
protein PA28 (PA28; LdBPK.35.2.000770). Genome-wide overexpression library screening with 449 
the established proteasome inhibitor compound 2 [compound 7 in (12)],  a close analogue of the 450 
clinical candidate for visceral leishmaniasis GSK3494245 (12, 32), confirmed that parasites 451 
“resistant” to this proteasome inhibitor were also found to overexpress PA28 (Figure 2C and 452 
Table S5). Indeed, compound 2-resistant L. donovani promastigotes, generated through in vitro 453 
selections, and subsequently found to bear a G197S mutation within the gene encoding the β5 454 
proteasome subunit, demonstrate considerable (260-fold) cross-resistance to compound 1 455 
(Table S6). These data, alongside our WGS analysis, strongly suggest that, like compound 2, 456 
compound 1 is a proteasome inhibitor in both L. donovani and T. cruzi.  457 
 458 
Target validation 459 
The proteasome is a key component of the ubiquitin-proteasome protein degradation system 460 
and plays a crucial role in numerous cellular processes, including protein turnover and cell 461 
signalling (33). In eukaryotes, the proteasome consists of a central 20S cylindrical core flanked 462 
by two regulatory complexes (19S). The canonical 20S unit is comprised of two outer (α) and 463 
two inner (β) polypeptide rings. Three of the β-type subunits are responsible for chymotrypsin-, 464 
trypsin-, and caspase-like catalytic activities. The proteasome is a well-exploited target in drug 465 
discovery for a variety of indications, including cancer, inflammation, and a number of infectious 466 
diseases (34). A number of recent studies have illustrated the utility of the proteasome as a 467 
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viable drug target in kinetoplastids (12, 13, 26, 35). Indeed, GSK3494245 and LXE408 (12, 35), 468 
inhibitors of the chymotrypsin-like activity of the Leishmania proteasome are being clinically 469 
assessed for use in the treatment of visceral leishmaniasis. These studies confirm the feasibility 470 
of selectively inhibiting of the kinetoplastid proteasome and the value of this molecular target for 471 
drug discovery.  472 
We next sought to interrogate the role of the proteasome in the MoA of compound 1. 473 
Like compound 1, compound 2 is active against both T. cruzi and L. donovani. Virtually all of our 474 
compound 1-resistant clones, with the exception of RES 4 (2.5-fold resistant), demonstrated 475 
considerable cross-resistance to this established proteasome inhibitor (20-127-fold, Table 2).  In 476 
addition, the broad-spectrum anti-kinetoplastid proteasome inhibitor GNF6702 (13) 477 
demonstrated similar levels of cross-resistance against RES 1-5 clones while there was no 478 
evidence of cross-resistance to the classical proteasome inhibitor bortezomib, used in the 479 
treatment of multiple myeloma, mantle cell lymphoma and a number of other cancers (36) (Table 480 
2). GNF6702, GSK3494245 and analogues are known to target the same allosteric binding site 481 
at the interface of the β4/β5 subunits of the proteasome resulting in the inhibition of 482 
chymotrypsin-like activity. Collectively, our data suggests that compound 1 targets this same 483 
allosteric binding site rather than the bortezomib binding pocket in the active site of β5. 484 
The impact of the β5 D225N mutation, identified in the majority of our resistant clones, 485 
was examined further. T. cruzi epimastigotes overexpressing the mutated version of the β5 486 
subunit were generated, with elevated levels of this mutated protein confirmed by quantitative 487 
RT-PCR (Figure S1). Epimastigotes overexpressing β5 D225N were found to be 8-fold less 488 
sensitive to compound 1 than wild-type parasites. These transgenic parasites also 489 
demonstrated considerable resistance to both compound 2 and GNF6702 (Table 2). 490 
Overexpression of β5WT in the RES 1 clone, which bears the D225N mutation, partially reverted 491 
the resistance phenotype of this cell line to all three compounds. CRISPR-Cas9 was used to 492 
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engineer specific mutations in the β4 subunit (F24L and I29M) previously shown to confer 493 
resistance to GNF6702 (13). CRISPR-edited epimastigotes were refractory to compound 1, 494 
compound 2 and GNF6702 at all the concentrations tested, once again linking the 495 
mechanism(s) of action/resistance of compound 1 with that of established proteasome 496 
inhibitors. Furthermore, these data strengthen our hypothesis that compound 1 exploits the 497 
same allosteric binding site at the interface of the β4/β5 subunits of the proteasome. 498 
The in vitro-selected, CRISPR-edited and overexpressing T. cruzi cell lines were also 499 
assessed against compound 1, GNF6702 and fexinidazole (control compound) as amastigotes 500 
within Vero cells (Table S7). The response to compound treatment and resistance/cross-501 
resistance profiles of these intracellular amastigotes closely mimicked that seen with their 502 
respective epimastigote cell lines. These data are consistent with compound 1 inhibiting the 503 
function of the proteasome in the clinically-relevant, mammalian stage of T. cruzi. 504 
 505 
Inhibition of proteasome activity 506 
Initially, the impact of compound 1 on the chymotrypsin-like proteolytic activity of the 507 
proteasome was assessed using a commercially available indirect enzyme-based luminescent 508 
assay. In this assay, activity is monitored in proteasome-enriched T. cruzi epimastigote lysates 509 
using Suc-LLVY-aminoluciferin as a substrate (12). Unfortunately, the data produced by this 510 
assay was unreliable with regard to compound 1, with IC50 values ranging from 0.9 to >15 µM 511 
reported. Based on these data and the statistics associated with the assay, it became clear that 512 
compound 1 directly interferes with the assay. Thus, an alternative route to determine the 513 
impact of this arylsulfonamide compound on T. cruzi proteasome function was required. 514 
In cells where the function of the proteasome has been compromised, there is a 515 
concomitant build-up of ubiquitinylated proteins earmarked for degradation. Here, 516 
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ubiquitinylated peptides were recovered from the lysates of epimastigotes pre-treated with 517 
bortezomib, compound 1 or compound 2 over 8h at concentrations equivalent to 3× their 518 
respective EC50 values. Control cultures were treated for the same period of time in the 519 
presence of DMSO. Enrichment of ubiquitinylated proteins was achieved by 520 
immunoprecipitation using magnetic beads conjugated to an antibody specific for the remnant of 521 
ubiquitinated lysines following digestion with trypsin and/or LysC. Using LC-MS/MS, the 522 
ubiquitination ratio of each sample was calculated by dividing the reporter intensity of 523 
ubiquitinated proteins by the reporter intensity of total protein (Table S8). As expected, the 524 
accumulation of ubiquitinylated proteins was highest in epimastigotes treated with bortezomib 525 
(2.7-fold higher than in the DMSO-treated control), known to inhibit all three catalytic activities of 526 
the proteasome (Figure 3). The build-up of ubiquitylated proteins in cells treated with GNF6702, 527 
an established inhibitor of the chymotrypsin-like activity of the proteasome, was clearly evident 528 
but more modest (1.45-fold higher than control). Similarly, ubiquitinylated proteins accumulated 529 
to levels 1.9-fold higher in compound 1-treated parasites compared to those recovered from 530 
DMSO-treated control cells.  These data are entirely consistent with our hypothesis that 531 
compound 1 acts principally as an inhibitor of the T. cruzi proteasome. 532 
 533 
Identification of a secondary target 534 
Thermal proteome profiling (TPP) can be used as an effective and unbiased approach to 535 
demonstrate compound-target engagement. It is based on the principle that binding of a drug to 536 
its protein target can significantly alter the thermal stability of that protein (37). Here, T. cruzi 537 
epimastigotes lysates were treated with compound 1 (10× established EC50 value) or DMSO 538 
vehicle. Aliquots of each lysate were then incubated at designated temperatures (33-69°C), and 539 
for each temperature, insoluble (denatured) proteins were removed. The resulting soluble 540 
protein samples were reduced, alkylated, and digested with trypsin prior to derivatization with 541 
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tandem mass tags. Pooled peptides were fractionated by HPLC and analyzed by LC/MS-MS 542 
prior to identification and quantitation. The melting points of identified proteins were then 543 
established using the TPP software package. Full melt curves were established for 6771 544 
proteins, representing 39.4% coverage of the T. cruzi proteome. The top 20 proteins 545 
demonstrating thermal shift in the presence of compound 1 in two separate replicate 546 
experiments are summarised in Tables S9 and S10. 547 
While TPP has proven effective in a number of our MoA studies to date (18, 22), 548 
experience indicates that it is less effective in cases where the molecular target is part of a large 549 
multi-subunit complex such as the proteasome. Indeed, analysis of our two independently 550 
generated TPP datasets failed to identify any subunits of the proteasome as targets of 551 
compound 1 (Tables S9 and S10). The only target candidate with significantly increased thermal 552 
stability in the presence of compound 1 across both datasets was the cytosolic T. cruzi malic 553 
enzyme (cTcME, C4B63_28g106) (38). Individual melting curves revealed that the thermal 554 
stability of cTcME increased by 8.8 °C (mean ΔTm) in experiment 1 and 5.5°C in experiment 2 555 
(Figure 4A, Tables S9 and S10). In contrast, compound 1 had no impact on the thermal stability 556 
of the mitochondrial version of this enzyme (mTcME, Figure 4B).  557 
ME catalyses the oxidative decarboxylation of malate to pyruvate with the concomitant 558 
reduction of NAD(P)+ to NAD(P)H.  In light of our TPP studies, we next sought to determine if 559 
the binding of compound 1 to cTcME inhibits enzymatic activity. The ME-dependent production 560 
of NADPH was monitored in clarified lysates of T. cruzi epimastigotes at 340 nm following the 561 
addition of malate. In the first instance, this assay was validated using ATR-073, an established 562 
inhibitor of cTcME (39). In keeping with previous studies (39), pre-incubation of lysates with 20 563 
µM ATR-073 resulted in a 96% reduction in ME activity while pre-treatment with 1 µM reduced 564 
activity by 63%. Similarly, pre-incubation of lysates with 20 µM and 1 µM of compound 1 565 
inhibited ME activity by 96 and 68%, respectively (Figure 4C). These data confirm compound 1 566 
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as an inhibitor of cTcME. It should be noted that ATR-073 and compound 1 are structurally 567 
similar, both being substituted N-phenyl aryl sulfonamides, this common moiety constituting the 568 
pharmacophore of this chemical series.  569 
In order to probe the role of cTcME inhibition in the MoA of compound 1, a clonal cell 570 
line overexpressing this enzyme was generated. Elevated levels of cTcME in transgenic 571 
parasites relative to wild-type were confirmed by label-free MS quantitation (Figure S2). In 572 
addition, using the previously described spectrophotometric assay, ME activity in cTcMEOE 573 
lysates was shown to be 4.4-fold higher than in comparable wild-type lysates (Figure 4D) 574 
confirming that overexpressed ME is enzymatically active. However, overexpression of cTcME 575 
had little or no effect on the potency of compound 1, and this was also the case for cTcME-576 
overexpressing amastigotes in Vero cell assays (Table S7) as well as cLdME-overexpressing L. 577 
donovani promastigotes (Table S6). Epimastigotes overexpressing cTcME also remained just 578 
as susceptible to ATR-073 as wild-type perhaps suggesting that ME is not the primary target of 579 
this compound (Table S11). It should also be noted that careful analysis of WGS data from our 580 
T. cruzi compound 1-resistant clones identified no CNV or SNP associated with cTcME, nor did 581 
screening of our genome-wide overexpression identify cTcME as a hit. We next investigated the 582 
possibility that ATR-073 may actually inhibit the T. cruzi proteasome.  Using an established 583 
luciferase-based biochemical assay (26), this compound had no effect on the chymotrypsin-like 584 
activity of the proteasome at concentrations up to and including 3.3 µM (Figure S3A). At 585 
concentrations above this threshold ATR-073 began to interfere directly with the assay. In 586 
addition, cell lines resistant to compound 1 and bearing mutations in the β4 and β5 subunits of 587 
the proteasome demonstrated no cross-reactivity to ATR-073 (Figure S3B).  Collectively, these 588 
data suggest that despite the structural similarities between ATR-073 and compound 1 that they 589 




Docking studies 592 
With the aim of defining the binding site of compound 1 and understanding the role of mutations 593 
in compound 1-resistance, a homology model of the T. cruzi β4 and β5 proteasome subunits 594 
was generated. This model was based on the L. tarentolae orthologue structure (PDB:6QM7) 595 
complexed with GSK34944245 (12). The L. tarentolae β4/β5 proteasome subunits share 78% 596 
overall sequence identity with their counterparts in T. cruzi (Figure S4). Indeed, the sequence 597 
identity of the GSK3494245 binding site is even greater, with only one of the 26 amino acids 598 
within 5Å of the ligand differing (S132 of the β5 subunit in T. cruzi is T122 in L. tarentolae).  As 599 
there are two tautomeric forms of the compound 1 pyrazole, both were docked into the model. 600 
The best docking poses of both tautomers occupy the same region occupied by GSK3494245 in 601 
the L. tarentolae cryoEM structure (12). The pyrazole moiety of compound 1 occupies the 602 
hydrophobic pocket formed by F24, I27 and I29 residues of the β4 subunit and Y223, V238 and Y246 603 
from β5. It also establishes a hydrogen bond with the backbone nitrogen of G239 in β5 (or S242 604 
side chain, depending on the tautomer). In this binding pose, compound 1 stacks with F24 from 605 
the β4 subunit, and the central phenyl ring is in close proximity to the β5 side chains of D225 and 606 
D226 while the sulphonamide points towards solvent, directing thedi-metoxy phenyl moiety into a 607 
groove defined by β4 residues Y25, Y26 and I27 side chains (Figure 5). Previous studies have 608 
shown that β5 residues D225 and D226 play an important role on the recognition of GSK3494245 609 
by establishing long-range electrostatic interactions with a positively charged patch resulting 610 
from the unevenly distributed electrons of the ligand (32). Analysis of the electrostatic potential 611 
surface (ESP) of compound 1 suggests a similar scenario where a moderately electron-deficient 612 
area on the side of the pyrazole and central phenyl rings, possibly accentuated by the electron 613 
withdrawing effect of the sulfonyl amide, establishes a favourable electrostatic interaction with 614 
the side chains of the β5 residues Y223, D225 and D226 (Figure S5). This is consistent with the 615 
reduction in affinity observed for compound 1 and GSK3494245 in the presence of the mutation 616 
28 
 
D225N in the β5 subunit, where the removal of the negatively charged side chain partially 617 
disrupts this favourable interaction. Based on the suggested mode of binding, I27 from β4 plays a 618 
critical role in defining the sub-pockets where the pyrazole and di-methoxy phenyl moieties of 619 
compound 1 bind, and its mutation would likely disrupt the binding of the ligand as evidenced by 620 




Multiple orthogonal genetic, biochemical and proteomics approaches identify the proteasome as 623 
the primary molecular target of an arylsulfonamide compound with potential for anti-chagasic 624 
drug discovery. The proteasome has long been considered a viable, theoretical drug target in 625 
trypanosomatids (40), largely based on the enhanced susceptibility of these parasites to 626 
established proteasome inhibitors relative to mammalian cells (26, 41). Several recent studies 627 
have validated this assumption, with two proteasome inhibitors now in clinical trials for use in 628 
the treatment of visceral leishmaniasis (GSK3494245 and LXE408). Both compounds are 629 
structurally related and exploit the same binding pocket at the interface of the β4/β5 subunits of 630 
the L. donovani proteasome (12, 13, 35). Binding to this site inhibits the chymotrypsin- but not 631 
the trypsin- and caspase-like activities of the Leishmania proteasome. Inhibitors that target this 632 
pocket demonstrate impressive selective inhibition of the parasite versus the human 633 
proteasome, and this has been attributed to sequence variability in the narrow hydrophobic 634 
pocket (12) while the corresponding pocket in the human proteasome is also more open, 635 
shallow and solvent-exposed. Despite sharing no structural similarity with either LXE408, 636 
GSK3494245 or analogues, in the current study we present multiple lines of evidence that 637 
compound 1 targets the equivalent binding pocket in the T. cruzi proteasome (Figures 5B and 638 
C). Thus, compound 1 represents a new scaffold capable of binding at the proteasome β4/β5 639 
subunit interface that may represent a suitable starting point for future anti-chagasic drug 640 
discovery. 641 
The structure of compound 1 closely resembles a series of compounds found to inhibit 642 
cTcME in a target-based high-throughput screen (39).  While our data indicate that compound 1 643 
directly binds to cTcME and inhibits enzymatic activity, this inhibition does not appear to drive 644 
potency in epimastigotes or intracellular amastigotes. However, we cannot rule out the 645 
possibility that cTcME inhibition in parasites where the function of the proteasome is also 646 
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compromised may contribute to compound 1 potency. To our knowledge, there is no direct 647 
evidence that either ME isoforms are essential in T. cruzi. In the related kinetoplastid T. brucei, 648 
RNAi studies in the insect procyclic stage of the parasite indicate that, while mME is essential in 649 
standard cell culture conditions, the cytosolic isoform is dispensable (42). Establishing whether 650 
cME is essential in T. cruzi will be important in understanding its precise role, if any, in the MoA 651 
of compound 1 and will also determine if this enzyme has any value for future Chagas’ disease 652 
drug discovery.  653 
Sub-populations of non-dividing intracellular amastigotes have been observed in both in 654 
vitro and in vivo T. cruzi infections. These “persister” parasites retain the ability to differentiate 655 
into infectious trypomastigote forms that can reactivate infection. Importantly, nonreplicating 656 
amastigotes are refractory to treatment with existing trypanocidal compounds, including the 657 
frontline therapy benznidazole (10). These observations have led many to associate dormancy 658 
with treatment failure and to suggest that only compounds capable of killing dormant forms 659 
should be pursued (11). Based on their reduced ability to express reporter proteins (10), it is 660 
assumed that persister amastigotes exist in a significantly reduced metabolic state concurrent 661 
with reduced protein synthesis. It is tempting to hypothesise that alongside reduced protein 662 
synthesis, the requirement to turnover proteins via the proteasome will be similarly reduced in 663 
persisters, leading to a decreased susceptibility to proteasome inhibitors.  However, the 664 
proteasome inhibitor GNF6702 dosed twice-daily at 10 mg kg−1 matched the efficacy of 665 
benznidazole in a mouse model of infection (13). All but one of the eight treated mice had no 666 
detectable parasites in blood, colon or heart tissue, even after 4 weeks of immunosuppression. 667 
It should also be noted that a modified treatment regimen where higher doses of benznidazole 668 
were given in pulses over prolonged periods resulted in sterile parasitological cure of multiple 669 
mouse models of infection (43). This high-dose, extended-time protocol is believed to improve 670 
benznidazole efficacy by challenging the stochastic, time-limited nature of dormant parasites in 671 
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T. cruzi infections. These exemplary studies provide a template for the effective use of 672 
promising compounds that potentially have a modest impact on persister parasites. Assessing 673 
the efficacy of known proteasome inhibitors, including compound 1, via this modified protocol 674 
should be a priority. 675 
In conclusion, here we have identified a novel pharmacophore capable of inhibiting the 676 
T. cruzi proteasome. Future studies should focus on optimising the drug-like properties of this 677 
promising compound in order to assess its efficacy in mouse models of Chagas’ disease. 678 
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Figure legends 696 
Figure 1: Structures of compounds used in this study. These compounds include: TCMDC-697 
143194, an N-aryl arylsulfonamides that originates from GSK’s kinetobox library (29); the anti-698 
cancer drug bortezomib, a peptidic boronic acid;  the xxxxxxx DDD01012248, a close analogue 699 
of the Leishmania clinical candidate and proteasome inhibitor GSK3494245 (12); the 700 
imidazotriazine GNF6702, a pan-active inhibitor of the kinetoplastid proteasome developed by 701 
Novartis (13); and the triazolopyrimidine ATR-073, a proposed inhibitor of T. cruzi malic enzyme 702 
(cytosolic) (39). 703 
Figure 2: Target deconvolution studies with compound 1. (A) Schematic representation of 704 
the generation of compound 1-resistant cell lines in T. cruzi epimastigotes. Each passage of 705 
cells in culture (circles) is indicated with cell lines 1-5 indicated in black, grey, blue, red, and 706 
green, respectively. (B) EC50 values for compound 1 were determined for WT (white circles) and 707 
cloned resistant cell lines I-V (black, red, blue, grey and green circles, respectively). These 708 
curves are the nonlinear fits of data using a two-parameter EC50 equation provided by GraFit. 709 
An EC50 value of 0.7 ± 0.01 µM was determined for compound 1 against WT promastigotes. 710 
EC50 values for resistant clones I-V were 23 ± 4, 16 ± 0.3, 13 ± 1, 11 ± 1 and 14 ± 6 µM, 711 
respectively. These EC50 curves and values are from one biological replicate, comprised of two 712 
technical replicates. Collated data sets reporting the weighted mean ± SD of multiple biological 713 
replicates are summarised in Table S4. (C) Genome-wide map indicating cosmid library hits 714 
from screening of compound 2 (upper panel) and compound 1 (lower panel). Primary “hits” on 715 
chromosome 35 indicated in green (LdBPK.35.2.000770 and LdBPK.35.2.0007800) with 716 
surrounding genes indicated in yellow. The blue/pink and black/green peaks indicate 717 
independent cosmid inserts in different orientations. Focus on barcodes flanking 718 
LdBPK.35.2.000770 and LdBPK.35.2.0007800 (lower panel inset). 719 
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Figure 3: Relative levels of ubiquitinylated proteins in compound-treated and untreated T. 720 
cruzi epimastigotes. LC-MS/MS was used to quantify ubiquitinylated proteins recovered from 721 
T. cruzi epimastigotes pre-treated (8 h) with bortezomib, GNF6702 or compound 1 at 722 
concentrations equivalent to 3× their respective EC50 values. Abundance of ubiquitinylated 723 
proteins relative to the levels in control cultures exposed to DMSO for 8 h are shown. Data is 724 
from one biological replicate. 725 
Figure 4: Interrogation of T. cruzi ME as a potential target of compound 1. TPP melt curves 726 
for cTcME (A) and mTcME (B) following incubation with compound 1 (red) or vehicle (0.1% 727 
DMSO, black). Data from technical replicates (circles and squares) are shown, and the mean 728 
shift in melting temperature (ΔTm) for cTcME in this biological replicate was 5.5°C. (C) 729 
Monitoring the effects ATR-073 and compound 1 pre-incubation on the ME-dependent 730 
production of NADPH in clarified lysates of T. cruzi epimastigotes following the addition of 731 
malate. Data represent enzyme activity relative to DMSO-treated control lysates and is the 732 
mean ± SD of >3 biological replicates. (D) Relative ME activity in wild-type and cTcMEOE cell 733 
lysates.  Data represent enzyme activity relative to wild-type and is the mean ± SD of >3 734 
biological replicates. 735 
Figure 5: Compound 1 binding hypothesis. (A) Best scoring binding pose for compound 1 736 
(green) in the T. cruzi homology model of the GSK3494245 binding site at the interface of the 737 
β4/β5 subunits of the proteasome. (B) Best scoring binding pose for compound 2, consistent 738 
with the pose observed in the cryoEM structure of L. tarentolae proteasome with the close 739 
analogue GSK3494245 (PDB 6QM7). (C) 2D ligand interaction diagram based on the best-740 
scoring docking pose for compounds 1 and 2. 741 
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EC50 values, µM 









BSF Hep G2 
 
3 ± 0.08 1.3 ± 0.2 0.1 ± 0.005 0.7 ± 0.1 8* 0.3 ± 0.013 23 ± 3 
EC50 values represent the weighted mean ± standard deviation of at least three biological replicates (n ≥ 3) with each biological 743 
replicate comprised of two technical replicates. * Intra-macrophage data from (29). 744 
 745 




Table 2 - Collated EC50 data for WT, resistant and transgenic T. cruzi epimastigote cell 748 
lines 749 
Cell line 
EC50 values, µM (fold change versus WT) 
Compound 1 Compound 2 GNF6702* Bortezomib 
Wild-type 3.3 ± 0.08 0.04 ± 0.001 0.3 ± 0.02 0.2 ± 0.004 
RES I 61 ± 1 (18) 4 ± 0.08 (100) >10  0.2 ± 0.004 (1) 
RES 2 54 ± 1 (16) 5 ± 0.2 (127) >10  0.3 ± 0.01 (1) 
RES 3 61 ± 0.7 (18) 5 ± 0.4 (120) >10  0.2 ± 0.08 (1) 
RES 4 31 ± 2 (9) 0.1 ± 0.01 (2.5) >10 0.6 ± 0.05 (2.5) 
RES 5 70 ± 2 (21) 0.8 ± 0.03 (20) 10 ± 0.2 (33) 0.2 ± 0.08 (1) 
β5D225N-OE 27 ± 1 (8) 2 ± 0.1 (58) > 10 (>28) 0.2 ± 0.008 (1) 
37 
 
All EC50 values represent the weighted mean ± standard deviation of at least three biological 750 
replicates (n ≥ 3) with each biological replicate comprised of two technical replicates. *Solubility 751 
issues >10 µM. 752 
  753 
Res 1-β5OE  13 ± 0.8 (4) 0.3 ± 0.01 (6.5) 2 ± 0.3 (6) 0.2 ± 0.005 (1) 
β4F24L/I29M > 50 (>15) > 10 (>250) > 10 (>28) 0.2 ± 0.005 (1) 
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